Yulia Slavina

Editas Medicine unveils cardiovascular research at ASGCT and TIDES USA events

Editas Medicine unveils cardiovascular research at ASGCT and TIDES USA events
Editas unveils gene therapy data

Editas Medicine is set to present new preclinical data this week at both the American Society of Gene and Cell Therapy (ASGCT) and TIDES USA annual meetings.

The focus will be on cardiovascular disease, with Editas Medicine highlighting novel in vivo research efforts. Details about the company's participation and presentations at each conference are available via their official channels.

Editas Medicine recently announced plans to present new preclinical data on gene editing at scientific conferences, with a focus on cardiovascular research earlier this year. The company also reported its first quarter 2026 financial results and provided updates on development programs in its latest earnings release. These developments reflect continued progress in Editas Medicine’s gene editing initiatives.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.